Raising the Medicaid rebate percentage and inflation penalty on accelerated-approval drugs, as the Medicaid and CHIP Payment and Access Commission (MACPAC) recommends, could lead to lower 340B ceiling prices on those drugs.

MACPAC Backs Medicaid Change That Could Lower Some 340B Prices

Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need. If Congress follows the advice, 340B covered entities might see lower ceiling prices on those drugs.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »